Thiophosphoric acid S-(2-diethylamino-ethyl) ester | 20194-80-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Thiophosphoric acid S-(2-diethylamino-ethyl) ester
• 英文别名: 2-(Diethylamino)ethylsulfanylphosphonic acid
• CAS: 20194-80-3
• 化学式: C₆H₁₆NO₃PS
• 分子量: 213.238
• InChiKey: RMRDGYWYMLAWNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  86.1
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] COMPOSITIONS, MATERIALS, AND METHODS FOR DEACTIVATING TOXIC AGENTS<br/>[FR] COMPOSITIONS, MATÉRIAUX ET PROCÉDÉS DE DÉSACTIVATION D'AGENTS TOXIQUES
  申请人：INST FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE INSTEM

  公开号：WO2019180653A1

  公开（公告）日：2019-09-26

  The present invention is related to a nucleophilic agent that includes a nucleophilic moiety and is capable of deactivating a toxic agent. The invention is also related to compositions or articles that include the nucleophilic agent. Methods of preparing and using the nucleophilic agents, the compositions and the articles are also included in the invention.

  本发明涉及一种包括亲核基团并能够使毒性剂失活的亲核试剂。该发明还涉及包括该亲核试剂的组合物或物品。发明还包括制备和使用亲核试剂、组合物和物品的方法。
• MULTIVALENT SYNTHETIC NANOCARRIER VACCINES
  申请人：Bratzler Robert L.

  公开号：US20110293701A1

  公开（公告）日：2011-12-01

  The invention relates, at least in part, to compositions comprising populations of synthetic nanocarriers that comprise different sets of antigens as well as related methods.

  该发明涉及至少部分包含不同抗原集合的合成纳米载体群体的组成物，以及相关方法。
• POLYTHIOUREA COMPOSITIONS AND METHODS OF USE
  申请人：EMPIRE TECHNOLOGY DEVELOPMENT LLC

  公开号：US20150344613A1

  公开（公告）日：2015-12-03

  Disclosed herein are compositions and methods of making polythiourea and polythiourethane foams and coatings. In one embodiment, a method of preparing a polythiourea composition involves combining at least one polyamine compound, at least one polyisothiocyanate compound, and at least one catalyst to form a reaction mixture, and mixing the reaction mixture to form the polythiourea composition. In some embodiments, the polyamine compound may have an amine functionality of two or more, and is present in an amount of about 14 wt % to about 40 wt % of the reaction mixture. In some embodiments, the polyisothiocyanate compound may have a functionality of two or more, and is present in an amount of about 60 wt % to about 86 wt % of the reaction mixture. In some embodiments, the catalyst may be present in an amount of about 0 wt % to about 5 wt % of the reaction mixture.

  本文公开了制备聚硫脲和聚硫脲酯泡沫和涂层的组合物和方法。在一种实施例中，制备聚硫脲组合物的方法包括将至少一种多胺化合物、至少一种多异硫氰酸酯化合物和至少一种催化剂组合形成反应混合物，并混合反应混合物以形成聚硫脲组合物。在一些实施例中，多胺化合物可能具有两种或更多的胺官能团，并且在反应混合物中的含量约为14重量％至约40重量％。在一些实施例中，多异硫氰酸酯化合物可能具有两种或更多的官能团，并且在反应混合物中的含量约为60重量％至约86重量％。在一些实施例中，催化剂可能在反应混合物中的含量约为0重量％至约5重量％。
• Vaccine nanotechnology
  申请人：Massachusetts Institute Of Technology

  公开号：EP2394657A1

  公开（公告）日：2011-12-14

  The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or in B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at least one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one vaccine nanocarrier to a subject in need thereof.

  本发明提供了向免疫系统细胞递送纳米载体的组合物和系统。本发明提供了能够刺激 T 细胞和/或 B 细胞免疫应答的疫苗纳米载体，在某些实施方案中，纳米载体包含至少一种免疫调节剂，可选地包含至少一种靶向分子和可选地包含至少一种免疫刺激剂。本发明提供了包含疫苗纳米载体的药物组合物。本发明提供了设计、制造和使用疫苗纳米载体及其药物组合物的方法。本发明提供了预防和/或治疗疾病、失调和病症的方法，包括向有需要的受试者施用至少一种疫苗纳米载体。
• Synthetic hapten carrier compositions and methods
  申请人：TRIA BIOSCIENCE CORP.

  公开号：US10111948B2

  公开（公告）日：2018-10-30

  The present disclosure relates to peptide monomers comprising an amphipathic ?-helical peptide, and optionally, at least one T cell epitope peptide; and to dimers and trimers comprising the peptide monomers. The monomeric, dimeric, and trimeric peptides may be conjugated to at least one hapten, wherein the hapten is linked to a lysine or aspartic acid residue of the peptide monomer. These peptide conjugates are useful as vaccine delivery vehicles.

  本公开涉及肽单体，包括两性螺旋肽和可选的至少一种T细胞表位肽；以及包括肽单体的二聚体和三聚体。单体肽、二聚体肽和三聚体肽可与至少一种合体素连接，其中合体素与肽单体的赖氨酸或天冬氨酸残基连接。这些多肽共轭物可用作疫苗递送载体。